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Abstract
Background: Insulin-like growth factor-II (IGF-II) promotes cell proliferation and survival and plays an important role in
normal fetal development and placental function. IGF-II binds both the insulin-like growth factor receptor (IGF-1R) and
insulin receptor isoform A (IR-A) with high affinity. Interestingly both IGF-II and the IR-A are often upregulated in cancer and
IGF-II acts via both receptors to promote cancer proliferation. There is relatively little known about the mechanism of ligand
induced activation of the insulin (IR) and IGF-1R. The recently solved IR structure reveals a folded over dimer with two
potential ligand binding pockets arising from residues on each receptor half. Site-directed mutagenesis has mapped
receptor residues important for ligand binding to two separate sites within the ligand binding pocket and we have recently
shown that the IGFs have two separate binding surfaces which interact with the receptor sites 1 and 2.
Methodology/Principal Findings: In this study we describe a series of partial IGF-1R and IR agonists generated by mutating
Glu12 of IGF-II. By comparing receptor binding affinities, abilities to induce negative cooperativity and potencies in receptor
activation, we provide evidence that residue Glu12 bridges the two receptor halves leading to receptor activation.
Conclusions/Significance: This study provides novel insight into the mechanism of receptor binding and activation by IGF-
II, which may be important for the future development of inhibitors of its action for the treatment of cancer.
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Introduction
The insulin-like growth factors (IGF-I and IGF-II) share
sequence and structural similarities with insulin. IGFs have four
domains in the order B, C, A, and D from the N terminus
(Figure 1) and three alpha helices making up the core structure.
Insulin is produced as a propeptide which, when processed to the
mature form, only has the B and A domains on separate chains
linked as a dimer by disulphide bonds and having a similar helical
structure to the IGFs. In contrast to the critical role of insulin in
metabolic control the IGFs act via the type 1 IGF receptor (IGF-
1R) to promote cell proliferation, survival and differentiation. IGFs
are essential for normal growth and development, and perturba-
tion of IGF-I expression is associated with acromegaly (increased)
[1] or short stature (decreased) [2]. Disruption of IGF-II
imprinting during development is associated with overgrowth in
Beckwith-Wiedemann syndrome, whereas reduced paternal allele
expression results in growth retardation in Silver-Russell syndrome
[3]. Furthermore, IGFs acting via the IGF-1R play a major role in
promoting cancer cell growth and survival [4]. Therefore
understanding the mechanism of receptor activation will aid in
the understanding of the role of these ligands in disease.
The insulin receptor (IR) exists in two isoforms which arise by
alternative splicing of exon 11 [5,6]. The IR-B isoform binds
insulin with high affinity. The IR-A isoform, which lacks the 12
amino acids normally encoded by exon 11, not only binds insulin
with high affinity but can also bind IGF-II, albeit with a 6 fold
lower affinity [7,8]. Whereas insulin promotes metabolic signalling
via both isoforms, interestingly, IGF-II predominantly promotes
activation of mitogenic signalling outcomes such as protection
from apoptosis via the IR-A [9,10]. Expression of IGF-II and IR-A
in foetal tissues is supportive evidence for the role of these
molecules in development [6]. Furthermore, expression of both is
upregulated in many cancer cells and tissues suggesting a role in
promoting cancer cell growth and survival [5,6] and explaining
the resistance of certain cancer cells to inhibition of growth by
anti-IGF-1R antibodies [11].
Activation of the IR and IGF-1R leads to signalling via two
main pathways. Following activation of the tyrosine kinase domain
the receptors undergo autophosphorylation, which promotes
binding of adapter molecules such as the insulin-receptor
substrates (IRS-1 and -2) and Shc. These proteins then led to
activation of the phosphatidylinositol 3-kinase (PI3K/Akt) and the
extracellular signal-regulated kinase (ERK/MAPK) cascades [12].
The IR and IGF-1R are structurally similar, each made of
homodimers with a 2a2b subunit configuration. The ectodomain
adopts a folded over conformation with two potential ligand
binding pockets [13]. Within a binding pocket there are two
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distinct binding surfaces: the L1 and FnIII-2 insert domains from
opposite receptor halves form one binding surface (site 1)
[13,14,15,16] and residues within the FnIII-1 and FnIII-2 domains
form the other surface (site 2) [17]. Each ligand binds the receptor
with a stoichiometry of 1:1 at physiological concentrations.
Binding of a second ligand molecule in the other binding pocket
accelerates the dissociation of the first resulting in a negative
cooperativity binding mechanism [18,19].
As there is currently no structure of these ligand:receptor
complexes our understanding of the mechanism of binding is
derived from mutagenesis and cross-linking studies. There is a
similar overall binding mechanism for the insulin:IR and the
IGF:IGF-1R interactions [20], although there is an additional
contact made between the IGF-I C-domain and the IGF-1R
cysteine rich (CR) domain [15,21]. Insulin has two distinct surfaces
(sites 1 and 2), which contact the IR. The site 1 insulin binding
surface includes residues ValB12, TyrB16, TyrB26, and ValA3
(residues corresponding to the dimerisation interface) and these
contact residues within the IR site 1 described above. Insulin
binding site 2 includes residues HisB10, GluB13, LeuB17, SerA12,
LeuA13 and GluA17 (Figure 1) [19]. Two similar sites also exist on
IGF-I and IGF-II although there are subtle differences in the
relative contribution of each residue to the receptor interactions
[22,23] (Figure 1).
So far there is little direct evidence of the mechanism by which
ligand binding results in receptor activation. Mutagenesis studies
suggest that the insulin site 2 residue HisB10 plays an important
role in IR activation and in particular mitogenic signalling. In this
study we aim to investigate our proposal that the equivalent site 2
residue of IGF-II (Glu12) may also be important for receptor
binding and activation. We describe a series of Glu12 mutants
which act as partial IGF-1R and IR agonists. We provide evidence
that site 2 residue Glu12 bridges the two receptor halves leading to
receptor activation by comparing receptor binding affinities,
abilities to induce negative cooperativity and potencies in receptor
activation. These findings provide strong evidence to support the
current model of receptor activation, which incorporates a
bridging event to initiate receptor activation and downstream
signalling. This study has therefore lead to a greater understanding
of the mechanisms of IGF-II binding and activation of the IGF-1R
and IR-A.
Results
Production and Structural Characterization of IGF-II
Mutants
Six IGF-II mutants with single amino acid substitutions (to Ala,
Asp, His, Lys, Gln and Arg) at the Glu12 position were produced
to analyse the contribution of this residue to receptor binding and
activation. All mutants were purified following successful expres-
sion in E.coli and were shown by mass spectrometry to be of the
correct mass. Expression and processing of Glu12Arg IGF-II was
considerably less efficient than for IGF-II and the other mutants.
The far-UV CD spectra for all the mutants, Glu12Arg IGF-II
included, were essentially identical to that of IGF-II (Figure S1),
indicating that the substitutions had little overall effect on
secondary structure.
IGF-1R and IR-A Binding
Binding to Solubilised Receptors. The affinities of the
Glu12 IGF-II mutants for detergent solubilised, immunocaptured
IGF-1R and IR-A were measured in competition binding assays
(Figure 2A and 2B). The IC50 values derived from these assays are
presented for each of the mutants as values relative to IGF-II in
Table 1. Alanine mutagenesis studies previously demonstrated that
meaningful changes in affinity resulting from single amino acid
substitutions range from 2- to 100-fold [24]. We therefore consider
here only .2-fold changes in affinity to be significant (fold change
refers to the ratio of the IC50 value of the analogue to the IC50
value of IGF-II). By this definition, five of the six mutants (all
but Glu12Asp IGF-II) had significantly lower affinities for the
solubilised IGF-1R than IGF-II (Figure 2A). Glu12Lys, Glu12Ala,
Glu12His and Glu12Gln IGF-II all had similar binding affinities
that were 36–43% of IGF-II, while replacement of Glu12 with Arg
caused the greatest disruption to binding (5.2-fold worse than IGF-
II). In contrast, only two of the six mutants displayed significant
decreases in affinity for the solubilised IR-A (Figure 2B, Glu12Lys
and Glu12Arg IGF-II with 2.3- and 2.4- fold lower affinities than
IGF-II respectively).
Binding to IGF-1R and IR-A on the cell surface. We and
others have previously shown that in some cases the effect of
mutations of insulin [25] or IGF [22,23] on their receptor binding
(including Glu12Ala in IGF-II [22]) is greater when measured on
receptors within the cell membrane than on solubilised receptors.
In the present study therefore, we also measured the IGF-1R and
IR-A binding affinities of the mutants (Figure 2C and 2D) using
P6-IGF-1R (BALB/c3T3 cells overexpressing the human IGF-1R)
[26] and R2IR-A cells (IGF-1R negative (R2) cells overexpressing
the IR-A) [8]. As expected all six mutants exhibited much lower
affinities for membrane bound IGF-1R (Figure 2C, 4.3–15.1 fold
lower than IGF-II) and IR-A (Figure 2D, 2.5–11.6 fold lower than
IGF-II) compared to the equivalent solubilised receptors (1.36–5.6
fold and 1.72–2.38 fold lower than IGF-II for the soluble IGF-1R
and IR-A respectively). Interestingly, Ala substitution was quite
detrimental when binding to both membrane-bound IGF-1R
(Figure 2C) and IR-A (Figure 2D) (10.4% and 14.2% of IGF-II
respectively), whereas it had relatively little effect on binding to
immunocaptured solubilised receptors (Table 1). For P6-IGF-1R
Figure 1. The amino acid sequence alignment of IGF-II, IGF-I, and insulin. Insulin residues important for IR binding and defined as site 1
residues (ValB12, TyrB16, GlyB23, PheB24, Phe B25, TyrB26, GlyA1, IleA2, ValA3, GlnA5, TyrA19, AsnA21) are shown in bold type and those defined as
site 2 residues (HisB10, GluB13, LeuB17, SerA12, LA13, Glu17) are underlined and in italics [18]. IGF-I and IGF-II site 2 residues are underlined and in
italics. Conserved residues are boxed in light gray, residues conserved between IGF-II and IGF-I are boxed in dark gray and the domain structure is
below. Residue Glu 12 of IGF-II mutated in this study is highlighted with an asterisk.
doi:10.1371/journal.pone.0027488.g001
Insulin and IGF-1 Receptor Activation by IGF-II
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binding, conservative substitutions of Glu12 with Asp or Gln
resulted in 4.3-fold decreases in affinities relative to IGF-II
(Figure 2C). Substitutions with the increasingly basic amino acids
His, Lys and Arg were the most detrimental to IGF-1R binding
with an 8.3-, 14.5- and 15.2 fold decrease in affinity relative to
IGF-II, respectively. The effect of these mutations on IR-A
Figure 2. Competitive binding of IGF-II and Glu12 mutants to IGF-1R and IR-A either solubilised or on intact cells. Immunocaptured
solubilised IGF-1R and IR-A (A and B) or P6 IGF-1R and R2IR-A cells (C and D) were incubated with Eu-IGF-II in the presence or absence of increasing
concentrations of IGF-II (N), Glu12Asp IGF-II (m), Glu12Ala IGF-II (&), Glu12Gln IGF-II (n), Glu12His IGF-II (#), Glu12Arg IGF-II (,) or Glu12Lys IGF-II
(%). Results are expressed as a percentage of binding in the absence of competing ligand (%B/Bo), and the data points are the mean6SEM of at least
three separate experiments with each point performed in triplicate. Error bars are shown when greater than the size of the symbols.
doi:10.1371/journal.pone.0027488.g002
Table 1. Relative binding of IGF-II and the IGF-II analogues for the IGF-1R and IR-A.
Affinity (%IGF-II ± SEM)
IGF-1R IR-A P6 IGF-1R R2IR-Ab R2IR-A/P6 IGF-1Rc
IGF-IIa 100 (3.660.6 nM) 100 (4.261.2 nM) 100 (1.160.3 nM) 100 (3.161.7 nM) 1.0
Glu12Ala 40.868.9*** 5769** 14.263.6*** 10.462.2*** 0.7
Glu12Asp 73.3612.4ns 5866* 23.265.7*** 39.7614.9*** 1.7
Glu12His 40.6613.3*** 52616** 1262.1*** 34.269.6*** 2.9
Glu12Lys 43.4612.2*** 4465*** 6.962*** 32.167.4*** 4.7
Glu12Gln 35.9610.3*** 56614** 2366.8*** 23.669.7*** 1.0
Glu12Arg 17.761.6*** 42618*** 6.661.5*** 8.664.5*** 1.3
aBinding affinities of the analogues relative to IGF-II were derived from the IC50 values. Relative binding is expressed as a percent of IGF-II 6 S.E. The IC50 of IGF-II for
each assay is shown in parentheses.
bBinding to R2IR-A =binding to R2IR-A cells, IR-A = to immunocaptured IR-A, P6 IGF-1R = to BALB/c3T3 cells overexpressing the IGF-1R, IGF-1R = to immunocaptured
IGF-1R.
cR2IR-A/P6 IGF-1R is the ratio of IC50 values for binding to the R2IR-A cells versus P6 IGF-1R. Data is derived from at least 3 separate experiments performed in triplicate.
*** = p,0.001,
** = p value 0.001 to 0.01,
* = p value 0.01 to 0.05, ns = not significant when compared to IGF-II.
doi:10.1371/journal.pone.0027488.t001
Insulin and IGF-1 Receptor Activation by IGF-II
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binding did not exactly parallel their effects on IGF-1R binding
(Figure 2D). Substitutions with Asp, Gln, His and Lys all had a
similar effect on R2IR-A binding (24–40% of IGF-II), with His
and Lys being tolerated on this receptor better than on the IGF-
1R in the membrane (R2IR-A/P6 IGF-1R ratio of 2.9 and 4.7
respectively, see Table 1). Arg and Ala substitutions caused the
greatest negative effect on R2IR-A binding with 10- and 12-fold
decreases in affinity compared to IGF-II, suggesting size and
charge may play a role in optimal binding.
Dose-response Curves for Negative Cooperativity
While there are two potential binding pockets in each receptor,
IGF-1R and IR binding studies indicate that only a single ligand
molecule bridges a pair of binding surfaces within a single pocket
at a time. The model of IGF-1R and IR binding proposed by De
Meyts [19] suggests that a second ligand molecule, upon partial
dissociation of the first (pre-) bound ligand, is able to bridge the
alternate binding site and thereby accelerates the dissociation of
the first ligand (defined as negative cooperativity). To assess the
effect of Glu12 substitutions on negative cooperativity we mea-
sured the ability of each analogue to accelerate the dissociation of
pre-bound europium-labelled IGF-II (Eu-IGF-II) in P6-IGF-1R
cells. Dissociation of Eu-IGF-II tracer from the IGF-1R by
unlabeled IGF-II produced a sigmoid dose response curve for
negative cooperativity with 26% of tracer remaining bound after
30 minutes (Figure 3A and 3B, 50%B/Bo at 4 nM). Interestingly,
the dose-response curve for Glu12Asp was indistinguishable from
that of IGF-II (Figure 3A) despite the 4-fold decrease in affinity of
Glu12Asp for P6-IGF-1R (Table 1). Glu12Gln had a ,2.5 fold
decrease in potency (indicated by the right shift in the dose-
response curve in Figure 3A, 50% B/Bo reached at 10.5 nM) in
line with its reduced affinity for the IGF-1R, and it did result in the
same maximal acceleration of dissociation of Eu-IGF-II (28% of
tracer remaining) as IGF-II. Glu12His (Figure 3A), Glu12Ala
(Figure 3B) and Glu12Arg (Figure 3B) (in that order) showed
further reduced potencies for negative cooperativity compared to
IGF-II as evidenced by the rightward shift of these curves and a
decrease in maximal dissociation of tracer (40–50% of tracer
remaining bound). Glu12Lys was also very poor at accelerating
dissociation of the Eu-IGF-II (Figure 3B). The reduced efficacy of
IGF-II mutants in these assays is consistent with a reduced ability
to bridge the alternate binding pocket. Dose-response curves for
negative cooperativity were unable to be obtained for IGF-II and
the IR-A on R2IR-A cells. The amount of tracer bound did not
provide a suitable window to discern the differences between IGF-
II and Glu12 IGF-II mutants. We suspect this is due to the lower
level of receptor expression on these cells than on the P6-IGF-1R
cells used for the IGF-1R assays and are exploring alternative
experimental systems to allow these measurements with the IR-A
in the future.
IGF-1R and IR-A Kinase Receptor Activation Assays
Activation of the IGF-1R on P6-IGF-1R cells and IR-A on
R2IR-A cells by Glu12 mutants was assessed by measuring their
capacities to stimulate total receptor tyrosine phosphorylation in
kinase receptor activation assays. The dose-response curve for
IGF-II-induced stimulation of IGF-1R (Figure 4A) in P6-IGF-1R
cells was bell-shaped, with maximal phosphorylation at 100 nM
IGF-II and self-antagonism apparent at higher concentrations.
The bell-shaped activation curve is indicative of a bivalent
bridging mechanism [27]. A similar curve has also been observed
for IGF-I activation of the IGF-1R [8,23] and is seen for insulin
activating the IR [8,27]. In the present study, a bell-shaped curve
was not observed for IGF-II-induced phosphorylation of the IR-A
(Figure 4B) within the concentration range explored and maximal
phosphorylation was still being approached at 1 mM.
For both the IGF-1R (Figure 4A) and IR-A (Figure 4B)
Glu12Asp was only slightly less potent than wild-type IGF-II (a
rightward shift of ,2 fold and .80% of maximal response) in its
ability to activate receptor phosphorylation. The remaining
mutants displayed reduced abilities to activate receptor phosphor-
ylation in terms of both rightward shift of the curve and maximal
response (decreased height of the curve). Glu12Gln induced
phosphorylation of both receptors to 65% of the maximum seen
for IGF-II and was slightly more potent than Glu12His. Glu12Ala
and Glu12Lys were poor activators of IGF-1R and IR-A achieving
just 24–32% of the maximum seen for IGF-II (Figure 4A and 4B
respectively). The ability of Glu12Arg to activate both receptors
was also significantly impaired and this was more so on the IGF-
1R (maximal response 30% of IGF-II, Figure 4A) than the IR-A
(maximal response 45% of IGF-II, Figure 4B).
Interestingly, the ability of each analogue to activate the
receptors in terms of both rightward shift of the curve and
maximal response essentially mirrored the relative potencies in the
Figure 3. Dose-response curves for negative cooperativity. Accelerated dissociation of prebound Eu-IGF-II in the presence of increasing
concentrations of (A) IGF-II (N), Glu12Asp IGF-II (m),Glu12Gln IGF-II (n), Glu12His IGF-II (#) and (B) IGF-II (N), Glu12Ala IGF-II (&), Glu12Arg IGF-II (,)
or Glu12Lys IGF-II (%) from the IGF-IR on P6 IGF-1R cells. Results are expressed as a percentage of binding in the absence of competing ligand (%B/
Bo) after 30 min, and the data points are the mean6SEM of three assays with each concentration measured in triplicate. Error bars are shown when
greater than the size of the symbols. Curves are separated into two graphs for clarity.
doi:10.1371/journal.pone.0027488.g003
Insulin and IGF-1 Receptor Activation by IGF-II
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dose-response curves for negative cooperativity. However, we
noticed a disparity for some mutants between receptor binding
affinities and activity in both kinase receptor activation assays and
dose response curves for negative cooperativity. For example,
Glu12Ala IGF-II, with only a 7 fold lower IGF-1R binding affinity
than IGF-II, required 100 fold more (300 nM) to achieve the same
level of IGF-1R phosphorylation as IGF-II (ie a rightward shift
when comparing concentrations required to achieve 30%
phosphorylation and accompanied by only a 32% maximal
response). The same could be said for Glu12Lys and Glu12Arg
IGF-II. Also, all three showed a disparity in IR-A binding affinity
and receptor activation activity. For example, Glu12Lys was a
significantly weaker agonist of the IR-A in these assays than
Glu12His (Figure 4B) despite their nearly identical IR-A binding
affinities (Table 1). In addition, Glu12Ala bound IR-A with 10 fold
lower affinity than IGF-II but 30 fold more Glu12Ala was required
to achieve the same level of IGF-1R phosphorylation as IGF-II (ie
a rightward shift when comparing concentrations required to
achieve 30% phosphorylation accompanied by only a 29%
maximal response). This is in contrast to IGF-I which, despite
poor IR-A binding affinity (14 fold lower than IGF-II [8]), was
able to activate the IR-A better than Glu12Ala IGF-II (Figure S2).
Finally, as Glu12Lys had less of an effect on IR-A binding
affinity than IGF-1R binding affinity (32% versus 6.9% of IGF-II
affinities respectively) it was a surprise to see an even greater
detrimental effect on IR-A activation than expected (Figure 4B)
Glu12Lys activated both the IR-A and IGF-1R to similar extents
and only to 25% maximal response). In conclusion, Glu12Ala,
Glu12Lys and Glu12Arg IGF-II exhibit a greater than expected
decrease in ability to activate both IGF-1R and IR-A compared to
their binding affinities for these receptors.
Phosphorylation of the downstream signalling molecule
Akt
In order to examine signalling downstream of the receptors,
activation of Akt in response to IGF-II and mutants was measured
in P6-IGF-1R (Figure 5A) and R-IR-A cells (Figure 5B). Activated
Akt (as measured by phosphorylation of Akt Ser473) was barely
detectable and not quantifiable under basal conditions (i.e. serum
free media) in either cell line. As shown in Figure 5A and 5B
10 nM IGF-II stimulated activation of Akt via both the IGF-1R
and IR-A (as measured by phosphorylation of Ser473) to the same
extent as 100 nM IGF-II. With the exception of Glu12Ala
treatment of P6-IGF-1R cells (43% of IGF-II, p.0.01), there was
no significant difference between the abilities of the Glu12 mutants
and IGF-II to activate Akt when 100 nM was used to stimulate
both P6-IGF-1R (Figure 5A) and R2IR-A cells (Figure 5B).
However, when the P6-IGF-1R or R2IR-A cells were stimulated
with 10 nM Glu12Arg, Glu12Ala or Glu12Lys IGF-II Akt
activation was significantly reduced 3.3- to 7.2-fold compared
with 10 nM IGF-II (Figure 5A and 5B respectively). Ten
nanomolar Glu12Asp, Glu12Gln and Glu12His induced Akt
activation to no less than half that seen with 10 nM IGF-II via
both receptors. Thus, Akt activation correlates with ability to
activate the receptors in the KIRA assays.
Discussion
IGF-II binds to the IGF-1R and the IR-A and activates
mitogenic signalling leading to cell proliferation and survival.
Receptor binding involves a two site binding mechanism [22].
With a series of six novel IGF-II mutants we have demonstrated
the importance of IGF-II residue Glu12 in IGF-1R and IR-A
binding and activation and have shown that both the size and
charge of the Glu sidechain at this position are important for
achieving high affinity binding of IGF-II to both receptors.
In this study introduction of a positive charge at position 12 of
IGF-II (as is found in the equivalent position in insulin (HisB10))
resulted in a lower affinity for both the IGF-1R and IR-A. A
positive charge at the same position in IGF-I (Glu9Lys) also results
in a lower affinity for the IGF-1R [28]. Conversely, substitution of
the insulin residue HisB10 with a negatively charged amino acid
(Asp or Glu) leads to an increase in IR and IGF-1R binding
affinity and is associated with an enhanced mitogenic activity
[29,30,31]. This suggests that a negative charge at this position in
all three ligands is preferable when striving for the highest receptor
binding affinity. However, the HisB10 found in insulin has
apparently been selected for to achieve optimal metabolic
signalling via the IR and confers to insulin the property of Zn2+
coordination in the hexameric form.
Interestingly the Glu to Lys or His charge reversals at position
12 of IGF-II had more effect on binding to the membrane bound
IGF-1R (8- to 14-fold lower than IGF-II) than IR-A (3-fold lower
than IGF-II). We conclude that while both receptors display a
Figure 4. Activation of the IGF-1R and IR-A by IGF-II and Glu12 mutants. P6-IGF-1R cells (A) and R2IR-A cells (B) were serum starved for 4 h
and then incubated with increasing concentrations of IGF-II (N), Glu12Asp IGF-II (m), Glu12Ala IGF-II (&), Glu12Gln IGF-II (n), Glu12His IGF-II (#),
Glu12Arg IGF-II (,) or Glu12Lys IGF-II (%) for 10 min. Solubilised IGF-1R (A) and IR-A (B) were immunocaptured, and phosphorylated tyrosines were
detected with Eu-PY20. Receptor phosphorylation is expressed as a percentage of the maximal phosphorylation induced by IGF-II. The data points are
means6SEM of three assays with each concentration measured in triplicate. Error bars are shown when greater than the size of the symbols.
doi:10.1371/journal.pone.0027488.g004
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preference for negative charge at the Glu12 position, the IR-A
displays a greater tolerance of positive charge here than the IGF-
1R. This points to a difference in the nature of the second binding
surface (i.e. that encountered by Glu12) on the IGF-1R and IR-A.
Differences in IGF-1R and IR site 2 regions was previously
demonstrated by Benyoucef et al. [32] in the context of an IGF-
1R:IR-A hybrid receptor, which normally has low affinity for
insulin. Introduction of the IR residues 325–524 (incorporating
some of binding site 2) into the corresponding region of the IGF-
1R half of the hybrid led to a 20-fold increase in insulin binding
affinity. Recently specific IR residues contributing to site 2 binding
were identified by site-directed mutagenesis [17] and some of these
residues are not conserved in the IGF-1R sequence. Further
mutagenesis studies would be required to identify which specific
residues within the IGF-1R and IR-A site 2 regions are responsible
for these differences in affinities for the Glu12Lys and Glu12His
mutants.
It is clear that the effect of mutating Glu12 in IGF-II (or the
equivalent residues in insulin [25] and IGF-I [23]) is greater on
membrane bound receptors than on soluble receptors. In the case
of insulin mutation of site 2 residues (SerA12, LeuA13, GluA17,
HisB10, and LeuB17 but not GluB13) produce mutants also with
different affinities for the two receptor forms [25]. A mathematical
model was recently reported describing the bimolecular reaction
between insulin and the IR, and IGF-I and the IGF-1R [33]. It
describes first the interaction at site 1 followed by an isomerisation
of this low affinity complex to a high affinity complex in which the
ligand bridges (‘‘cross-links’’) the receptor between sites 1 and 2,
with both sites acting in trans from each receptor half. The
difference in affinity of mutations at Glu12 for membrane-bound
versus soluble receptors could be explained in context of the
mathematical model (below). The overall binding affinity is
dependent on the rate at which the cross-link is formed (kcr). An
increase in kcr results when the receptor is in the soluble form due
to removal of the tethering constraint of the cell membrane
leading to a higher binding affinity [33]. A decrease in affinity
following mutation of the ligand site 2 residues (which are involved
in the isomerisation) is more readily detected using membrane-
bound receptor where the ability to form the cross-link is reduced
due to a lower kcr arising from membrane tethering.
LzR0
?a1
/
d1
R1
/kcr
/
d2
R1x2
L= ligand, R0= apo receptor, a1 = association rate at site 1,
d1 = dissociation rate at site 1, R
1 = receptor:ligand complex with
binding to site 1 only, kcr = cross-linking constant, d2 = dissociation
of ligand from site 2, R162 = cross-linked receptor:ligand complex
[33].
While the stoichiometry of ligand binding by the IGF-1R and
IR is 1:1 at physiological concentrations there are two potential
ligand binding pockets within each receptor’s structure. This
allows for the characteristic property of accelerated dissociation
and negative cooperativity exhibited by both receptors (as
described earlier). Here we report the negative cooperativity of
IGF-II binding to membrane-anchored IGF-1R. At the concen-
tration range used (up to 1 mM) we observed a sigmoidal dose
response curve for negative cooperativity (Figure 3), as is seen for
IGF-I on the IGF-1R (membrane bound and solubilised receptor)
and IGF-II on solubilised IGF-1R [34,35]. Interestingly, mutation
of Glu12 resulted in a significantly decreased ability to accelerate
dissociation, a phenomenon also seen when mutating IGF-I at the
equivalent positions to Ala [19,23]. This is consistent with the
notion that mutation of Glu12 decreases the efficiency with which
IGF-II bridges receptor sites 1 and 2 and thus implies a key role for
this residue in that process.
A major difference in the mechanism of interaction of IGF-II
with the IGF-1R and insulin with the IR is the shape of the dose
response curve for negativity cooperativity (sigmoidal versus bell-
shaped respectively). The ability of the ligand to accelerate
dissociation of tracer is dependent on the ability, upon partial
dissociation of the first, to form the alternate cross-link (ie binding
of another ligand at site 1 and site 2 in the alternate pocket). The
reversal of negative cooperativity (which leads to insulin’s bell-
Figure 5. Induction of Akt phosphorylation upon IGF-1R and IR-A activation by IGF-II and Glu12 mutants. Serum-starved P6 IGF-1R (A)
and R2IR-A cells (B) were treated with IGF-II, Glu12Asp IGF-II, Glu12Ala IGF-II, Glu12Gln IGF-II, Glu12His IGF-II, Glu12Arg IGF-II or Glu12Lys IGF-II at
10 nM (hatched bars) or 100 nM (solid bars) for 10 min. Whole-cell lysates were prepared and subjected to SDS-PAGE and then immunoblotted for
phosphorylated Akt (pAkt). Representative blots are shown in the lower panels, and lanes 1–9 are 10–15 are from separate blots in both A and B. Each
blot included lanes from cells untreated (basal) and treated with 100 nM IGF-II. In upper panels densitometry of three independent experiments 6
SEM are shown as a column graph. Relative pAkt levels are expressed as a fraction of the level detected when cells were stimulated with 100 nM IGF-
II. In each case pAkt was expressed as a fraction of the loading control (b-tubulin). a=p value,0.001 , b=p value 0.001 to 0.01, c=p value 0.01 to
0.05 when compared to IGF-II at the same concentration.
doi:10.1371/journal.pone.0027488.g005
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shaped curve) is thought to be due to two monovalent interactions
of insulin at the alternate pocket, one at site 1 and the other at site
2. As the property of negative cooperativity is dependent on
interactions at site 2 [19,36] it is most likely the shape of the curve
arises due to subtle differences in the site 2 interaction. Indeed
Christoffersen et al. [37] demonstrated a bell-shaped curve with
IGF-I when using a chimeric IGF-1R with residues 392–579 of the
IR (incorporating site 2) inserted into the equivalent region of the
IGF-1R. It remains to be determined whether IGF-II is able to
induce a bell-shaped dose response curve for negative cooperativ-
ity when binding the IR.
The common feature of negative cooperativity and receptor
activation is the process of bridging or ‘‘cross-linking’’ the two
receptor halves. Consistent with our notion that mutation of Glu12
decreases the efficiency with which IGF-II bridges receptor sites 1
and 2, we see a correlation between a decreased potency in
negative cooperativity assays and the ability to activate the
receptor by our Glu12 mutants (kinase receptor activation assay).
Glu12Ala, Glu12Lys and Glu12Arg IGF-II mutants are also
significantly less potent than IGF-II in their abilities to activate
phosphorylation of Akt via both the IGF-1R and IR-A.
Furthermore, the Glu12Ala, Glu12Lys and Glu12Arg substitu-
tions have a greater than expected decrease in receptor activation
compared to their corresponding binding affinities. The disparate
receptor binding and activation seen for the IGF-II E12 mutants
(and equivalent insulin and IGF-I residues) has not been observed
for other IGF-II site 2 residues (Phe19, Leu53, and Glu57) [22].
Therefore, we conclude that the interaction between Glu12 and
site 2 residues on both the IGF-1R and IR-A plays an important
role in receptor activation by promoting cross-bridging of the two
receptor halves and that receptor binding affinity is not necessarily
a true indicator of potency in receptor activation. A similar
phenomenon was observed when the corresponding residue of
insulin HisB10 was substituted with Asp. There were 2 and 5.8
fold increases in IR and IGF-1R binding respectively with a
concomitant 2 fold increase in metabolic signalling but an
unexpected ,10 fold increase in mitogenic signalling [31]. It
would be interesting in the future to see if the disproportionate
effect of the IGF-II Glu12 substitutions on receptor activation
leads to different biological outcomes compared to IGF-II.
The current findings suggest that Glu12 of IGF-II and the
corresponding residues in both IGF-I and insulin play an
important role in receptor activation through their ability to
interact with site 2 on the receptors. The cross-bridging of the two
receptor halves involving this residue is crucial in the process of
receptor activation. Understanding the mechanism of IR and IGF-
1R activation is critical for the future design of insulin mimetics
and inhibitors of IGF action for the treatment of diseases such as
diabetes and cancer.
Materials and Methods
Materials and Cell Lines
LongTMR3IGF-I was purchased from Novozymes GroPep Pty
Ltd (Adelaide, South Australia). The DELFIA Europium-labeling
kit was purchased from PerkinElmer (Turku, Finland). Europium
labeled IGF-II (Eu-IGF-II) was produced according to the
manufacturer’s instructions and as described by Denley et al. [8].
Europium-labeled antiphosphotyrosine antibody PY20 was pur-
chased from Perkin Elmer Life Sciences. P6-IGF-1R cells (BALB/
c3T3 cells overexpressing the human IGF-1R) [26] were a kind
gift from Professor R. Baserga (Philadelphia, PA). IGF-1R
negative (R2) cells overexpressing the IR-A (R2IR-A) were
generated as described [8].
Construction and Expression of Plasmids Encoding
Human IGF-II Glu12 Mutants
The IGF expression vector was developed by King et al. [38]
and IGF-II cDNA introduced into the vector as previously
described [39]. The QuikChange site-directed mutagenesis kit
(Stratagene) was used to incorporate codons for Ala, Arg, Asp,
Gln, His and or Lys at position 12 of IGF-II (Glu in hIGF-II). The
resultant IGF-II mutants were expressed in E. coli JM101 (lac Iq) or
BL21 (DE3) as fusion proteins with the first 11 amino acids of
porcine growth hormone ([Met 1] pGH (1–11)) after isopropyl b-
D-thiogalactoside induction. Inclusion bodies were isolated as
previously described [38].
Purification of IGF-II Mutants
IGF-II mutants were purified as previously described [40] and
shown to have the correct masses by matrix-assisted laser desorption
ionization time-of-flight (MALDI-TOF) mass spectrometry (Dr
Chris Bagley and Mr Chris Cursaro, Adelaide Proteomics Facility).
Purity (.95%) was measured by reverse phase HPLC. All IGF-II
mutants maintained the same fold as native IGF-II, as determined
by far UV circular dichroism spectral analysis, as previously
described [40] (Figure S1). Quantitation of mutants was performed
by comparing analytical C4 HPLC profiles with profiles of standard
LongTMR3IGF-I preparations [41].
Binding Assays
Receptor binding affinities [IC50] were measured in two
different competition binding assay formats using Eu-IGF-II as
the tracer. Whole cell binding assays with P6-IGF-1R and R2IR-
A cells were performed as described by Alvino et al. [22]. Binding
to solubilised IGF-1R and IR-A immunocaptured from P6 IGF-
1R and R2IR-A lysates was as described previously [8,22].
Dose-Response Curves for Negative Cooperativity
Dose-response curves for negative cooperativity were performed
essentially as described in Gauguin et al. (2008) [23] but with some
minor modifications. Briefly, serum starved P6-IGF-1R cells
(26107 cells/ml) were incubated with Eu-IGF-II (26106 counts/
tube) in Hepes/BSA (100 mMHepes, 120 mM NaCl, 5 mMKCl,
1.2 mM MgSO4, 8 mM glucose, 0.5% BSA) for 2 h at 16uC.
Then 46106 cells in 20 ml were added to 180 ml ice-cold Hepes/
BSA containing increasing concentrations of IGF-II or mutants.
After 30 min dissociation at 16uC cells were washed in 400 ml ice-
cold tris buffered saline. Cell pellets were resuspended in 100 ml
enhancement solution (Perkin Elmer Life Sciences), incubated in
the dark for 30 min and then transferred to a white Greiner
Lumitrac 600 96-well plate. Time-resolved fluorescence was
measured using 340 nm excitation and 612 nm emission filters
with a BMG Lab Technologies Polarstar fluorometer (Germany).
Assays were performed in triplicate at least three times.
IGF-1R and IR-A Kinase Receptor Activation Assays
Receptor tyrosine phosphorylation was measured using an
adapted kinase receptor activation assay method [42] as previously
described [8,22]. P6-IGF-1R and IR-A cells were stimulated with
ligands and phosphorylated receptors in cell lysates were detected
with the europium labeled anti-phosphotyrosine antibody PY20
(Perkin Elmer Life Sciences). Assays were performed in triplicate
at least three times.
Immunoblots
P6-IGF-1R and R2IR-A cells were treated with 10 nM or
100 nM ligand for 10 min after a 4-hour treatment with serum
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free DMEM (1%BSA). Cells were lysed in 20 mM HEPES,
150 mM NaCl, 1.5 mM MgCl2, 10% (v/v) glycerol, 1% (v/v)
Triton-X 100, 1 mM EDTA, (pH 7.5) with freshly added 0.1%
(v/v) phosphatase inhibitor cocktail, 2 mM sodium orthovanadate
and 10 mM sodium fluoride. Protein concentration was deter-
mined with a Bradford protein assay kit (Bio-Rad). Lysates (40 mg)
were subjected to reducing SDS-PAGE (7.5% glycine gel). Blots
were probed with the polyclonal anti-phospho-Akt S473 (Bio-
source, Camarillo, CA). Consistency of loading was determined by
probing blots with anti-tubulin (Sigma). Blots were stripped in
62.5 mM Tris-HCl (pH 6.8), 2% SDS and 100 mM b-mercap-
toethanol for 30 min at 60uC. One-way ANOVA followed by
Dunnett’s test were used for all statistical analyses. Significance
was accepted at P,0.05. Blots were performed at least three times.
Supporting Information
Figure S1 Far UV circular dichroism spectra of IGF-II
mutants. The mutants have CD spectra indistinguishable from
that of IGF-II. The CD spectra of the mutants Glu12Asp IGF-II,
Glu12Gln IGF-II and Glu12Lys IGF-II A and of Glu12Ala IGF-
II, Glu12His IGF-II and Glu12Arg IGF-II B are superimposed on
the CD spectrum of IGF-II.
(TIF)
Figure S2 Activation of the IR-A by Insulin, IGF-I, IGF-II
and Glu12Ala IGF-II. R2IR-A cells were serum starved for 4 h
and then incubated with increasing concentrations of insulin (R),
IGF-I (e), IGF-II (N) and Glu12Ala IGF-II (m) 10 min.
Solubilised IR-A were immunocaptured and phosphorylated
tyrosines were detected with Eu-PY20. Receptor phosphorylation
is expressed as a percentage of the maximal phosphorylation
induced by insulin. The data points are means6S.E. of three
assays with each concentration measured in triplicate.
(TIF)
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